Microbot Medical Wins FDA Clearance for Liberty Endovascular Robotic System

Microbot Medical has received FDA 510(k) clearance for its Liberty Endovascular Robotic System, paving the way for commercialization in the U.S. The single-use, remotely operated system is designed for peripheral endovascular procedures, a market with approximately 2.5 million annual cases.

Liberty allows physicians to guide instruments remotely via a video game-style controller, reducing radiation exposure and physical strain. The system aims to improve maneuverability, simplify setup, lower costs by removing the need for expensive surgical tools, and eliminate reliance on dedicated cath-lab infrastructure.

In a multi-center study, Liberty achieved a 92% reduction in radiation exposure, 100% navigation success to target sites, and zero device-related adverse events. Microbot ended June with $4.1 million in cash and later secured a $630,000 grant to bolster manufacturing for commercialization. The company enters a market previously pursued by Siemens Healthineers and faces competition from European rival Robocath’s R-One+ platform.

16-09-2025